Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Parathyroid hormone 7-34

Drug Profile

Parathyroid hormone 7-34

Alternative Names: Parathyroid hormone 7-34 - IGI; PTH (7-34); PTH 7-34; PTHrP (7-34)

Latest Information Update: 16 Jul 2016

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator IGI
  • Developer Boston University; Teligent
  • Class Chemoprotectants; Peptide fragments; Peptide hormones
  • Mechanism of Action Parathyroid hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Alopecia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Alopecia in USA (Topical, Cream)
  • 09 May 2007 IGI receives STTR grant from the US National Cancer Institute for development of PTH 7-34 in chemotherapy-induced Alopecia
  • 13 Dec 2005 IGI has extended its exclusive license from Novavax for the use of Novasome® lipid vesicle encapsulation technology, micellar nanoparticles, and the Ultrasponge® Technology until December 2015
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top